Loading…

Evaluation of pneumococcal urinary antigen testing for respiratory tract infection investigations

•This study evaluated the use of pneumococcal urinary antigen testing for the diagnosis of lower respiratory tract infections, and identified factors associated with positive results to this test. To our knowledge this was the first study to assess the association between the pneumococcal urinary an...

Full description

Saved in:
Bibliographic Details
Published in:Médecine et maladies infectieuses 2020-02, Vol.50 (1), p.57-62
Main Authors: Charton, F., Conan, P.L., Le Floch, H., Bylicki, O., Gaspard, W., Soler, C., Margery, J., Rivière, F.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•This study evaluated the use of pneumococcal urinary antigen testing for the diagnosis of lower respiratory tract infections, and identified factors associated with positive results to this test. To our knowledge this was the first study to assess the association between the pneumococcal urinary antigen test result and clinical, biological, and radiological data in real life. This study is a first step in the research for well-reasoned prescription of pneumococcal urinary antigen test to reduce prescriptions and cost. The pneumococcal urinary antigen test enables rapid bacteriological diagnosis in respiratory tract infections. The objective was to identify factors associated with a positive pneumococcal urinary antigen test result. This seven-year retrospective monocentric study was performed on consecutive patients presenting with respiratory tract infections reported as pneumococcal-positive. Epidemiological, biological, and radiological factors were analyzed, and severity scores were calculated. A total of 223 patients were included. Significant associations were observed between positive test results and age over 65years (P=0.01), positive test results and immunosuppression factors (blood disease [25% Ag+ group vs. 4% Ag− group, P=0.001], immunosuppressive therapy [10% Ag+ group vs. 0% Ag− group, P=0.02]). Clinically, fever (64% Ag+ group vs. 42% Ag− group, P=0.01) and cough (46% Ag+ group vs. 19% Ag− group, P
ISSN:0399-077X
1769-6690
DOI:10.1016/j.medmal.2019.06.009